| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Gemcitabine | GDSC1000 | pan-cancer | AAC | 0.0083 | 0.8 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0079 | 0.8 |
| mRNA | Erlotinib | UHNBreast | pan-cancer | AAC | -0.062 | 0.8 |
| mRNA | BRD-K16130065 | CTRPv2 | pan-cancer | AAC | 0.015 | 0.8 |
| mRNA | BEC | CTRPv2 | pan-cancer | AAC | 0.015 | 0.8 |
| mRNA | ifosfamide | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | CIL56 | CTRPv2 | pan-cancer | AAC | 0.0093 | 0.8 |
| mRNA | lapatinib | CTRPv2 | pan-cancer | AAC | -0.0073 | 0.8 |
| mRNA | Cisplatin | GDSC1000 | pan-cancer | AAC | 0.0072 | 0.8 |
| mRNA | GSK269962A | GDSC1000 | pan-cancer | AAC | 0.0066 | 0.8 |